Navigation Links
Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
Date:9/26/2013

NEW HAVEN, Conn., Sept. 26, 2013 /PRNewswire/ -- Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced it has raised $15 million in Series A funds and $4.25 million in financial support, $1 million of which is in the form of equity, from the Connecticut Department of Economic and Community Development and Connecticut Innovations. Investors in the Series A round include co-leads Canaan Partners and 5AM Ventures along with Connecticut Innovations and Elm Street Ventures. The funds will support the development of the company's technology which has primary application in multiple oncology indications and potential in inflammatory, autoimmune and rare diseases.

Arvinas is built on the research of Craig Crews, PhD, Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and professor of Chemistry and Pharmacology at Yale University. The new drugs being developed by Arvinas would induce a cell's own protein-degradation capabilities to bind to a particular protein and "label" it for degradation, thus removing a protein from the system entirely. This contrasts to a more traditional drug development approach that inhibits proteins.  However, only 25 percent of the body's 20,000 proteins can be inhibited. Proteins that cannot be inhibited can potentially be degraded using Arvinas' approach, radically expanding the number of disease-causing proteins that can become the targets of new drugs.

"Degrading proteins as opposed to inhibiting them has potential to open up areas of drug development that were previously closed because of the technical limitations of protein inhibition," said Tim Shannon, MD, CEO of Arvinas and Venture Partner at Canaan Partners. "The Arvinas technology platform represents an entirely new class of drugs bringing an innovative approach to treating disease."

"In
'/>"/>

SOURCE Arvinas Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Predilytics Secures Additional Funding and Expands Board of Directors
2. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
3. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
4. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
5. Endexx Secures Exclusive World Wide Rights for Medical Marijuana Dispensing Technology
6. BioMotiv Secures $46 Million in Funding
7. Stark Medical Secures GSA Schedule Contract, Looks to Supply VA
8. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
9. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
10. SecureState Identifies Top 5 Vulnerabilities Facing Hospitals and Medical Device Manufactures
11. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/19/2014)... Friday, December 19 edition of USA ... features Konica Minolta, the company announced today. The supplement will focus ... organizations. In addition to the print section that ... New York , Chicago , ... Minneapolis and San Francisco , a ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... Feb. 16, 2012 Mylan Inc. (Nasdaq: ... ) today announced that Meridian Medical Technologies, a Pfizer ... and Sanofi-Aventis that will resolve pending patent litigation related ... epinephrine auto-injector known as e-cue™, which will be manufactured ...
... Acknowledging the importance of dedicated information management systems ... demonstrate the most recent version of its MOSAIQ® ... and Management Systems Society,s 2012 conference (HIMSS12), Feb. ... is a comprehensive OIS that centralizes traditional radiation ...
Cached Medicine Technology:Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 2Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 3Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 4Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 5Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2
(Date:12/24/2014)... In June 2014, 15 injured veterans ... hand cycles and recumbent bicycles nearly 800 miles from ... CanAm Veterans’ Challenge . “Capital to Capital,” the new ... this inspiring ride, is now available through multiple online ... photographs taken during the two-week ride, the 92 page ...
(Date:12/24/2014)... -- Each year, more than one-third of the more ... because of extreme heat conditions, according to recent federal ... stroke is the leading cause of heat-related illness among ... urinary tract infections, also put older people at higher ... data should help health care systems anticipate and perhaps ...
(Date:12/24/2014)... (HealthDay News) -- Though most patients with obsessive-compulsive disorder ... between 10 percent to 20 percent have a form ... experts say. However, patients with this so-called "refractory ... type of brain surgery that disables certain brain networks ... distinguish between patients most likely to benefit from the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
(Date:12/22/2014)... December 22, 2014 Fad diets ... The reason why most fad diets have hung around ... problem with fad diets is that, as the body becomes ... dieter uncertain of how to reset the metabolism to return ... Diet Doc developed their all-inclusive diet plans that ...
Breaking Medicine News(10 mins):Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4
... In conjunction with HBO, Cox Communications will allow all digital ... -- to have free access to its upcoming documentary series ... access all four documentaries in the series via Cox,s On ... to the programs through June 8th. "Cox is happy to ...
... The Healthcare Group at Frost & Sullivan ... Briefing Presentation on the Pharmaceutical CRM Market to be ... GMT. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )2008 has ushered in ... The pharmaceutical industry is adopting a cautious approach, delaying ...
... epitomizes the collaborative development process of software developer, PercipEnz Technologies, Inc. ... user interface but also incorporates over 200 enhancement requests provided by ... ... 27, 2009 -- The latest version of the OnCore(r) clinical ...
... Inc. (ARI) announced today it has launched Phase 2 of its clinical ... ... GA (PRWEB) April 24, 2009 -- Aderans Research Institute Inc. (ARI) announced ... hair regeneration for men and women. Structured around the findings of the ...
... malpractice challenge by introducing low tech solution to ... standardized shift reporting and note taking to help ... day tasks.RNReport Card is more efficient by standardizing ... fits conveniently in the pocket of your scrubs ...
... Flexibility and High-Content Screening ThroughputSUNNYVALE, CA, April ... leader in innovative solutions for drug discovery ... the Society for Biomolecular Sciences (SBS) Conference ... availability of the MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 ...
Cached Medicine News:Health News:Cox Communications Offers Free Access to HBO(R) Documentary Series, The Alzheimer's Project, to All Digital Customers 2Health News:Frost & Sullivan: The Pharmaceutical Customer Relationship Management Market - What are the Emerging Trends and Opportunities? 2Health News:Frost & Sullivan: The Pharmaceutical Customer Relationship Management Market - What are the Emerging Trends and Opportunities? 3Health News:OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development 2Health News:OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development 3Health News:OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development 4Health News:Aderans Research Launches Second Phase of Hair Loss Study 2Health News:RN Sisters Bring Low-Tech Innovations to New Nurses and Nursing Students 2Health News:MDS Analytical Technologies Releases MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 Cellular Imaging Software 2Health News:MDS Analytical Technologies Releases MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 Cellular Imaging Software 3
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
Direct antigen rapid immunoassay for the detection of Shiga toxin-producing E. coli 0157, which aids in the diagnosis of E. coli 0157:H7 infection...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Inquire...
Medicine Products: